Serum TSH level: Always the first step to assess functional status. c
Thyroid Ultrasound (US): Performed in all patients to evaluate nodule size and sonographic risk features.
Confirmatory/Gold Standard:
Fine Needle Aspiration (FNA): Cyto-pathological evaluation guided by US features and TSH results.
Key Labs:
TSH: Crucial for determining the initial diagnostic pathway.
Serum Calcitonin: Checked if medullary thyroid cancer (MTC) is suspected (e.g., family history or MEN2 features).
Imaging:
Thyroid US: High-risk features include microcalcifications, hypoechogenicity, irregular margins, a taller-than-wide shape, and interrupted rim calcifications.
Radionuclide Scintigraphy (I-123 or Tc-99m): Indicated only if TSH is suppressed/low.
“Hot” (hyperfunctioning) nodule: High uptake. Malignancy risk is <1%; FNA is not required.
“Cold” (nonfunctioning) nodule: Low uptake. Higher malignancy risk; requires US evaluation and potential FNA.
Management
First-line (Initial Algorithm):
Measure serum TSH.
If TSH is low -> Perform radionuclide scintigraphy.
If “hot” -> Evaluate and treat hyperthyroidism (methimazole, radioactive iodine [RAI], or surgery).
If “cold” -> Perform thyroid US and proceed to FNA if size/US risk criteria are met.
If TSH is normal or high -> Perform thyroid US. Proceed to FNA based on size and US risk features (e.g., solid hypoechoic ≥\ge≥1 cm, or any nodule ≥\ge≥1.5–2 cm).
Second-line (Based on FNA Cytology):
Benign (Bethesda II): Clinical and US monitoring in 6–12 months.
Indeterminate (Bethesda III/IV): Repeat FNA, perform molecular/genetic testing, or proceed to diagnostic lobectomy.
Suspicious/Malignant (Bethesda V/VI): Surgical resection (lobectomy or total thyroidectomy).
Levothyroxine suppression therapy to keep TSH suppressed (usually <0.1–0.5 mU/L) to prevent recurrence of TSH-sensitive thyroid cancer.
Toxic Adenoma
Pathophysiology/Etiology
A toxic adenoma is a benign, solitary thyroid nodule that autonomously produces excessive thyroid hormone, independent of TSH regulation.
This leads to hyperthyroidism, which can be overt (low TSH, high T4/T3) or subclinical (low TSH, normal T4/T3).
The underlying cause is often a somatic activating mutation in the TSH receptor (TSHR) or Gs-alpha gene, leading to constitutive hormone production.
More common in women, older adults, and individuals in iodine-deficient regions.
Clinical Presentation
Symptoms of Hyperthyroidism: Weight loss despite increased appetite, heat intolerance, sweating, anxiety, palpitations, tremors, and fatigue.
Local Symptoms: A palpable, often painless, neck nodule. Large nodules may cause dysphagia or a feeling of fullness in the throat.
Unlike Graves’ disease, there are no autoimmune features like exophthalmos or pretibial myxedema.
Diagnosis
Thyroid Function Tests (TFTs): Show a low or undetectable TSH with an elevated free T4 and/or T3.
Radionuclide Thyroid Scan (Scintigraphy): This is the key diagnostic test. It reveals a focal area of intense radioiodine uptake (a “hot nodule”) with suppressed uptake in the surrounding thyroid tissue.
Thyroid Ultrasound: Used to assess the size and characteristics of the nodule.
Antibodies: TSH receptor antibodies (TRAb) are absent, which helps differentiate it from Graves’ disease.
DDx (Differential Diagnosis)
Graves’ Disease: Also causes hyperthyroidism but is an autoimmune disorder. Diagnosis is supported by positive TSH receptor antibodies (TRAb), diffuse uptake on thyroid scan, and clinical signs like exophthalmos.
Toxic Multinodular Goiter (TMNG): Presents with multiple “hot” nodules on thyroid scan, often in older patients from iodine-deficient areas.
Thyroiditis (Subacute/Painless): Causes transient hyperthyroidism due to hormone leakage from an inflamed gland, resulting in decreased radioiodine uptake.
Management/Treatment
Symptom Control: Beta-blockers (e.g., atenolol) are used initially to manage adrenergic symptoms like palpitations and tremors.
Definitive Treatment: The goal is to eliminate the hyperfunctioning nodule. Options include:
Radioactive Iodine (RAI) Therapy (I-131): The most common treatment in the U.S. The “hot” nodule preferentially takes up the I-131, leading to its destruction. This has a high success rate and a low risk of subsequent hypothyroidism compared to RAI for Graves’ disease.
Surgery (Thyroid Lobectomy): Recommended for patients with large nodules causing compressive symptoms, if malignancy is suspected, or when RAI is contraindicated (e.g., pregnancy).
Antithyroid Drugs (e.g., Methimazole): Used to achieve a euthyroid state before definitive therapy but are not a long-term solution as hyperthyroidism typically recurs after cessation.
Key Associations/Complications
Complications: Untreated hyperthyroidism can lead to cardiac complications (e.g., atrial fibrillation) and bone loss (osteoporosis).
Prognosis: Excellent with definitive treatment. Toxic adenomas are almost always benign.
Buzzwords: “Hot nodule” on thyroid scan, absent TRAb, focal/unilateral hyperthyroidism.